Authors' response to a reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'

Br J Dermatol. 2017 Feb;176(2):552-553. doi: 10.1111/bjd.15204. Epub 2017 Jan 25.

Authors

D L Damian^{1

2

3}, A J Martin⁴, R A Scolyer^{2

3

5}, A C Chen^{1

2}, G M Halliday^{1

2}

Affiliations

¹ Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.
² Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
³ Melanoma Institute Australia, Sydney, Australia.
⁴ NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
⁵ Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.

PMID: 27893156
DOI: 10.1111/bjd.15204

No abstract available

Publication types

Letter
Comment

MeSH terms

Chemoprevention
Humans
Kidney Transplantation*
Niacin
Niacinamide*
Skin Neoplasms / prevention & control

Substances

Niacinamide
Niacin